LexaGene’s MiQLab™ System Selected to be a Best in Show Spotlight at the 47th Annual Industry Petcare Innovation Summit
October 27 2021 - 7:45AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)
(“LexaGene” or the “Company”), a molecular diagnostics company
that has commercialized an instrument for automated multiplex PCR
testing for veterinary diagnostics, today announced it has been
selected as a Best in Show Spotlight company at the Petcare
Innovation Summit to be held in Boston, MA in early December.
Dr. Jack Regan, LexaGene’s CEO and Founder stated, “It is an
honor to have LexaGene selected amongst the many applicants. I’m
pleased the selection committee recognized how innovative and
revolutionary the MiQLab System is for the veterinary industry. The
MiQLab allows for in-hospital evidence-based decision making so
antimicrobials are only prescribed when necessary and are
appropriately selected. I’m excited to have LexaGene lead the way
to promote a new wave of diagnostic testing for the veterinary
market. This speaking engagement gives the Company the opportunity
to speak directly to industry leaders as well as investors focused
on funding innovative life sciences companies.”
Start-ups and emerging pet care brands are invited to the
Petcare Innovation Summit where introductions can accelerate
growth, strengthen the investment pipeline, and expose brands to
executives who are looking for game-changers within the
industry.
According to the Summit organizers:
- more than 110 billion U.S. dollars will be spent in the pet
industry in 2021
- more than 65 percent of all U.S. families own a pet
- during the COVID-19 pandemic, nearly one in three Americans
adopted a pet
- millennials now represent the biggest share of pet owners in
the U.S.
Dr. Regan continued, “The veterinary industry is booming and
we’re not seeing any indication of it slowing down. Most
veterinarians are overwhelmed by the flood of new pets from
pandemic-fueled adoptions and LexaGene’s MiQLab system offers these
veterinarians a much more efficient way to diagnose and treat
animals – which will minimize the number of return visits due to
unresolved infections.”
The 47th Annual Petcare Innovation Summit will be held in
Boston, MA, on December 7-8 at the Hilton Back Bay Hotel. To
register for the conference, visit their website.
LexaGene’s MiQLab System is designed for in-clinic use and
screens for common bacterial infections and antimicrobial
resistance factors, returning results in ~ 2 hours versus multiple
days for laboratory-based results.
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing, and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Corporate & Media Contact:
Gail Winslow
Director of Marketing
gwinslow@lexagene.com
978.482.6237
ir@lexagene.com
800.215.1824
Investors:
Sharon Choe
Vice President
LaVoieHealthScience
schoe@lavoiehealthscience.com
(857) 241-7393
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024